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Abstract
Background: The hematopoietic Granulocyte-Colony Stimulating Factor (G-CSF) plays a crucial
role in controlling the number of neutrophil progenitor cells. Its function is mediated via the G-CSF
receptor, which was recently found to be expressed also in the central nervous system. In addition,
G-CSF provided neuroprotection in models of neuronal cell death. Here we used the retinal
ganglion cell (RGC) axotomy model to compare effects of local and systemic application of
neuroprotective molecules.
Results: We found that the G-CSF receptor is robustly expressed by RGCs in vivo and in vitro. We
thus evaluated G-CSF as a neuroprotectant for RGCs and found a dose-dependent
neuroprotective effect of G-CSF on axotomized RGCs when given subcutaneously. As stem stell
mobilization had previously been discussed as a possible contributor to the neuroprotective effects
of G-CSF, we compared the local treatment of RGCs by injection of G-CSF into the vitreous body
with systemic delivery by subcutaneous application. Both routes of application reduced retinal
ganglion cell death to a comparable extent. Moreover, G-CSF enhanced the survival of
immunopurified RGCs in vitro.
Conclusion: We thus show that G-CSF neuroprotection is at least partially independent of
potential systemic effects and provide further evidence that the clinically applicable G-CSF could
become a treatment option for both neurodegenerative diseases and glaucoma.
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Granulocyte-Colony Stimulating Factor (G-CSF) pro-
motes the survival, differentiation and proliferation of
cells of the neutrophilic lineage [1,2]. It belongs to the
group of lineage-specific hematopoietic colony growth
factors. However, G-CSF is able to pass the blood-brain-
barrier despite of its high molecular weight [3]. Moreover,
in the central nervous system (CNS) G-CSF is produced
endogenously by neurons and its production can be
enhanced by exogenous stimuli such as hypoxia [3]. The
G-CSF receptor (G-CSFR), which is a single transmem-
brane protein, was recently found to be widely expressed
in the CNS of adult rodents and humans [3]. Recom-
binant G-CSF was first approved by the FDA in 1991 for
the treatment of patients with chemotherapy-induced
neutropenia to lower the incidence of infections [4], and
thus is a well established clinical drug with a favourable
safety profile. Besides occasional bone pain, subcutane-
ous administration of G-CSF results in elevated white
blood cell counts. However, long-term application of G-
CSF for patients with chronic neutropenia was safe, partic-
ularly in regard to hematological malignancies [5-8].
In analogy to its anti-apoptotic effect in the hematopoietic
system, G-CSF was recently found to reduce infarct vol-
ume and to improve functional recovery in rodent studies
of acute and subacute stroke [3,9-18]. Consequently, sev-
eral stroke trials on humans have been conducted (for
review see: [19,20]). One small study with 10 patients
showed reduced functional deficits after 6 months of
treatment compared to the control group [21]. Recently,
we corroborated the neuroprotective effect of G-CSF in the
MPTP model of Parkinson's disease [22] and G-CSF was
furthermore shown to attenuate striatal degeneration in a
rodent model for Huntington's disease [23]. Moreover,
elevated G-CSF levels were found in patients with amyo-
trophic lateral sclerosis, suggesting a possible endogenous
neuroprotective effect of G-CSF for chronic neurodegener-
ative diseases [24,25]. In addition to direct neuroprotec-
tive and -regenerative effects mediated by G-CSFR
expressed in the CNS, indirect mechanisms based on sys-
temic G-CSF effects have also been discussed, such as
immunomodulatory effects or the mobilization of bone
marrow stem cells [18].
Here, we study the neuroprotective effect of G-CSF in the
rat optic nerve (ON) transection model. ON axotomy
leads to retrograde degeneration of 85% of the retinal gan-
glion cells (RGCs) within 14 days. In contrast to most
other in vivo models for neurodegeneration, death of axot-
omized RGCs fulfils all criteria of apoptosis [26-29].
Besides classic morphological signs [28], axotomized
RGCs show activation of caspase-3 and -9 [29-31] antago-
nistic regulation of Bax and Bcl-2 expression [26], down-
regulation of apoptosis-inhibiting activities of RAS/RAF/
ERK or PI3K/Akt kinases [29,30,32] and protective effects
of caspase inhibitors [29,31] and neurotrophins
[29,30,33]. Due to the possibility of either systemic or
intraocular application, the optic nerve transection para-
digm permits to compare both routes of application for
neuroprotective agents.
The ON axotomy model is thus an elegant in vivo para-
digm for neurodegenerative diseases. In addition, with
respect to the pressure-induced axonal damage found as a
pathophysiological mechanism in glaucoma, it also
reflects the selective degeneration of RGCs in this ophtal-
mological disease, which often continues despite ade-
quate lowering of the intraocular pressure [34-36].
In summary, we found further evidence suggesting that G-
CSF, a drug which has been in clinical use for almost
twenty years with a very good safety record, is a potential
clinical treatment option for both neurodegenerative dis-
eases and glaucoma. Moreover, we show that in the in vivo
model used here, local application of G-CSF to retinal
ganglion cells is sufficient to induce neuroprotective
effects independent of systemic mechanisms.
Results
G-CSF receptor expression in retinal ganglion cells in vivo
Using immunohistochemical staining with an antibody
raised against the C-terminus of the G-CSFR we found
expression in the retinal ganglion cell layer (Fig. 1A, C).
DAPI counterstaining showed that immunoreactivity
could be found on RGC somata, but no axonal or den-
dritic staining was observed. G-CSFR staining was largely
restricted to the RGC layer, with only low immunoreactiv-
ity, hardly exceeding background levels, in the remaining
retinal layers. Prelabelling of RGCs by injection of a retro-
grade tracer (Fluorogold; Fluorochrome) into the superior
colliculus, resulting in retrograde, specific staining of
RGCs, demonstrated that almost all RGCs were immuno-
reactive for G-CSFR protein (Fig. 1D). G-CSFR immunore-
activity remained unchanged 4 and 7 days after axotomy
(data not shown).
In vivo protective effects of systemic G-CSF application
Based on the positive G-CSFR immunoreactivity on RGCs,
we asked whether G-CSF is able to prevent RGC degener-
ation following axotomy due to optic nerve transection.
Similar to earlier data [37,38], we observed 420.6 ± 58.4
surviving RGCs/mm2 14 days after optic nerve transection
and daily subcutaneous vehicle injection (see material
and methods; Fig. 2A, C). Based on G-CSF dosing in pre-
vious in vivo neuroprotection experiments [3,22], we then
applied a daily dose of 20 or 40 μg/kg bodyweight (BW)
G-CSF subcutaneously, with the first injection approxi-
mately 2 h after axotomy. While application of 20 μg/kg
BW showed a non-significantly enhanced survival ofPage 2 of 10
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2B), a dose of 40 μg/kg BW G-CSF s.c. resulted in a highly
significant neuroprotective effect (742.3 ± 25.8 RGCs/
mm2; p < 0.001; table 1, Fig. 2B, C).
Next, we tested whether additional pre-treatment with 40
μg/kg BW G-CSF s.c. starting one day before axotomy
could further increase RGC survival. We found that this
pre-treatment resulted in a slight, but non-significant
increase in RGC numbers compared to treatment starting
after the lesion (771.3 ± 60.3 RGCs/mm2; table 1).
G-CSF enhances survival of immunopurified RGCs 
deprived of neurotrophic factors
Although distinct neuronal subtypes express the G-CSFR,
indirect mechanisms based on systemic G-CSF effects
have also been discussed as a mechanism for G-CSF neu-
roprotection. Therefore, in order to find further evidence
for a direct action of G-CSF on RGCs, we employed immu-
nopurified rat RGC cultures. Immunopurified rat RGCs
provide a well-established in vitro model for studies on
retinal ganglion cell death and apoptosis of CNS neurons
in general. Moreover, they share important aspects of cell
survival mechanisms with in situ RGCs [39-41]. A two-
step immunopurification protocol [42] was used to purify
RGCs to near homogeneity. Subsequently the cells were
cultured in serum-free medium, supplemented with the
neurotrophic factors forskolin, human BDNF, CNTF, and
insulin (see material and methods). G-CSFR expression in
purified RGCs was confirmed by RT-PCR and immunocy-
tochemistry (Fig. 3A–C). After 1 day in culture, neuro-
trophins were withdrawn, and the number of surviving
RGCs was determined after an additional 2 d in vitro.
When G-CSF was added concomitantly with the neuro-
trophin deprivation, survival of immunopurified RGCs
was enhanced significantly (Fig. 3D), suggesting a direct
neuroprotective effect of G-CSF on RGCs.
Topical application is sufficient for G-CSF-mediated 
neuroprotection in vivo
Our in vivo optic nerve transection paradigm offers the
advantage that protective compounds can be applied
locally to the neuronal population of interest by direct
intravitreal injection. We thus performed intravitreal
injections of vehicle or G-CSF at days 0, 4, 7 and 10 after
axotomy (500 ng G-CSF per injection in a volume of 2 μl,
first injection approximately 2 h after the axotomy) in
order to test whether systemic effects are required for G-
CSF neuroprotection in vivo. We confirmed that, in con-
trast to the expected higher leukocyte counts after subcu-
taneous G-CSF application, the intraocular injection
protocol did not increase blood leukocyte numbers (Fig.
4A). In agreement with the observed protective effect of G-
CSF on purified RGCs in culture, we found that direct
intraocular application of G-CSF was sufficient for neuro-
protective effects (681.8 ± 35.8 surviving RGCs/mm2; p <
0.05 compared to vehicle control), and did not signifi-
cantly differ from the effect of 40 μg/kg BW G-CSF given
subcutaneously (Fig. 4B; table 1).
Discussion
G-CSFR expression on neurons has been demonstrated
few years ago [11], and G-CSFR expression by neuronal
and non-neuronal cells has recently been identified in
G-CSF receptor is expressed in retinal ganglion cells of the rat retinaFigure 1
G-CSF receptor is expressed in retinal ganglion cells of the rat retina. Robust G-CSFR immunoreactivity was detected 
in the RGC layer (A-C). RGCs were specifically labelled with the fluorescent tracer Fluorogold in (D). G-CSFR labelling in (E) 
shows that all RGCs expressed G-CSFR protein. Only faint G-CSFR immunoreactivity was detected in outer retinal layers (A-
C). FG: Fluorogold; RGCL: retinal ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; ONL: outer nuclear 
layer.Page 3 of 10
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Table 1: Summary of in vivo RGC counts. Systemic and topical application of G-CSF or vehicle. 
Experimental Group Animal RGCs per mm2 Mean S.E.M.
axotomy + vehicle injection s.c. 1 360
2 348
3 594
4 379 420.6 58.4




5 365 402.2 15.5
axotomy + G-CSF 20 μg/kg BW s.c. daily 1 669
2 442
3 554
4 649 578.9 52.0




5 773 742.3 25.8
axotomy + G-CSF 40 μg/kg BW s.c. daily (start 1 d before surgery) 1 641
2 876
3 696
4 872 771.3 60.3
axotomy + G-CSF 500 ng i.o. on days 0, 4, 7 and 10 after axotomy 1 638
2 613
3 773
4 703 681.8 35.8
Cell numbers are given as mean ± S.E.M. s.c.: subcutaneous; i.o.: intraocular; BW: bodyweight.
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types, it was lately found to be expressed by neuronal pop-
ulations that are subject to cell death in neurodegenera-
tive diseases, e.g. motoneurons [[24,25], own
unpublished observation] or dopaminergic neurons in
the substantia nigra [22,43].
Similar to the expression pattern of the erythropoietin
receptor (EPOR), another hematopoietic cytokine with
neuroprotective action, we show for the first time consti-
tutive expression of the G-CSFR on the somata of RGCs.
In contrast to the EPOR [38] we could not find G-CSFR
expression on the dendrites of the RGCs in vivo. Our find-
ing that the G-CSFR is expressed by RGCs prompted us to
investigate possible neuroprotective effects of G-CSF on
RGCs. We demonstrate profound neuroprotection against
axotomy-induced RGC death through G-CSF. 40 μg/kg
BW s.c. lead to a significant attenuation of RGC cell loss
after optic nerve transection even when G-CSF was given
after lesioning. The mode of RGC death in the model we
used was shown to homogenously exhibit classical fea-
tures of apoptosis [26-31]. Thus, based on the large body
of evidence showing almost exclusively apoptotic cell
death in this paradigm, the substantial reduction in RGC
death can be explained by an anti-apoptotic activity of G-
CSF. An impact of G-CSF on other confounding parame-
ters, e.g. on the retrograde transport of Fluorogold, is the-
oretically possible. However, retrograde Fluorogold
labelling of RGCs is already completed two days after
axotomy [44], while rats were processed 14 days after
axotomy in our experiments. Moreover, Fluorogold was
proven to be a reliable marker for RGC survival that corre-
lates well with markers for apoptosis, also under treat-
ment with protective neurotrophins or cytokines in
several studies [30,33]. Finally, our data from purified
RGC primary cultures further support an anti-apoptotic
effect of G-CSF independent from retrograde axonal dye
transport.
It has been postulated that G-CSF may confer an improved
outcome in animal stroke models by bone marrow stem cell
mobilization and migration to the lesion site, followed by
neuronal differentiation [12]. Additional systemic mecha-
nisms could be postulated, as G-CSF has prominent systemic
anti-inflammatory properties [45] that might contribute to
its neuroprotective action in this model. In the experimental
autoimmune encephalitis (EAE) model of multiple sclerosis,
G-CSF was found to reduce T-cell-recruitment to the CNS
and protected from further inflammation [46]. Moreover, G-
CSF could be neuroprotective by indirect mechanisms, e.g.
inducing the release of neurotrophic factors from glial cells
[47]. However, G-CSF might also act directly on neural cells
after systemic application as it passes the intact blood brain
barrier [3]. Furthermore, we [[22], this study] and others
[3,11] found the G-CSFR expressed on neuronal target cells,
and neuroprotection was described in cultures of neuronal
cell lines free of non-neuronal cells, suggesting a direct pro-
tective action of G-CSF within the nervous system [3,22].
Our data presented here show that local application of G-
CSF to the retina is sufficient to induce neuroprotection in
vivo. Moreover, the results from our in vitro experiments
using primary cultures of immunopurified RGCs argue in
favour of a direct inhibition of neuron-specific apoptotic
pathways by activation of neuronal G-CSFR. Nevertheless,
this does not exclude an additional contribution of the
above mentioned indirect mechanisms, e.g. glial cell-derived
neurotrophic factors. Similarly, potential systemic effects
that might partially contribute to G-CSF neuroprotection
beyond its local activity can not be excluded at this point.
G-CSF protects RGCs after optic nerve transactionFigure 2
G-CSF protects RGCs after optic nerve transection. 
Subcutaneous daily injection of G-CSF (B, C) dose-depend-
ently attenuated RGC apoptosis after optic nerve transection 
when compared to vehicle injection (A, C). 14 days after 
optic nerve transection reduction in RGC loss was statisti-
cally significant at a dose of 40 μg/kg bodyweight s.c. when 
the first injection was performed approximately 2 h after the 
optic nerve transection. Starting G-CSF injection one day 
before axotomy (40 μg/kg + 1 d) resulted in a slight, but non-
significant increase in RGC numbers compared to treatment 
starting after the lesion. Panels (A) and (B) show an eccen-
tricity at one half of the retinal radius. * p < 0.05 (20 vs. 40 
μg/kg bodyweight); ** p < 0.01 (40 μg/kg or 40 μg/kg + 1 d 
vs. vehicle); n.s. = not significant. Data are given as mean ± 
S.E.M.Page 5 of 10
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after local injection of G-CSF could become of clinical rele-
vance if, in order to avoid potential unwanted systemic
effects of G-CSF, intracerebral or intrathecal administration
will be tested in future treatment studies for neurodegenera-
tive diseases.
In contrast to most other neurotrophic molecules, G-CSF
is already used in clinical practice for many years to treat
neutropenic patients, e.g. after chemotherapy or in cases
of severe congenital neutropenia. Especially the latter
application, which often requires G-CSF treatment for
many years, yielded valuable safety data showing that also
long-term treatment with G-CSF is principally possible
[7]. Thus, G-CSF could be immediately transferred to clin-
ical studies. Nevertheless, a safety record for the chronic
treatment of neurodegenerative diseases with G-CSF, also
with respective dose-finding studies, will have to be per-
formed in phase IIa/b studies.
As already outlined in the introduction, cell death in our
optic nerve transection model displays the properties of
classical neuronal apoptosis. Therefore, it provides an ele-
gant opportunity to study potential new treatment con-
cepts for neurodegenerative diseases in an in vivo model.
In addition, our model replicates important steps in the
G-CSF promotes survival of immunopurified rat RGCs after neurotrophic factor deprivationFigure 3
G-CSF promotes survival of immunopurified rat RGCs after neurotrophic factor deprivation. RGCs from 6- to 8-
day old rat pups were immunopurified and cultured under full neurotrophic support for 24 hours before neurotrophins were 
withdrawn. (A) RT-PCR from primary RGCs demonstrates G-CSFR expression at the mRNA level. The resulting PCR product 
has the expected 233 bp size. (B, C) G-CSFR immunocytochemistry on primary RGCs demonstrates receptor expression at 
the protein level. (C) shows higher power magnification. (D) RGCs were cultured under full neurotrophic support for 24 h. 
Cells were then deprived of neurotrophins, and at the same time G-CSF (1, 10, 50 or 100 ng/ml) or vehicle was added. The 
number of surviving RGCs was determined by MTT staining after an additional 2 days in vitro. A bell-shaped dose-response 
curve is observed, demonstrating significantly enhanced survival of RGCs compared with the vehicle-treated control cultures 
at a concentration of 10 and 50 ng/ml. * p < 0.05 (compared with vehicle). Data are given as mean ± S.E.M.Page 6 of 10
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due to increased ocular tension are thought to induce ret-
rograde RGC death and vision loss [48-50]. Therefore,
besides its potential usefulness for the treatment of neuro-
degenerative diseases, G-CSF may also be a powerful add-
on drug to stop RGC degeneration and to stop or slow
down vision loss, especially since lowering the intraocular
pressure does not necessarily halt the continuous degener-
ation of RGCs. Further, autoantibody-induced RGC apop-
tosis is a possible mechanism of autoimmune retinopathy
in cancer patients and may represent another potential
therapeutic application for G-CSF in ophthalmology [51].
Conclusion
In summary, we provide further support for the use of G-
CSF as a neuroprotective molecule that could be trans-
ferred to clinical application in the near future. We dem-
onstrate that G-CSF exerts neuroprotection after local
delivery to CNS neurons in vivo and may also become a
valuable therapeutic option in ophthalmology.
Methods
Transection of the optic nerve, retrograde labelling, tissue 
processing, and cell counting
Adult female Sprague-Dawley rats (200–250 g) were pur-
chased from Charles River, Wiga, Germany. Animals were
housed in plastic cages under standard laboratory condi-
tions. For a more detailed review of the surgery and tissue
processing see Kermer et al. [32] Briefly, animals were anaes-
thetized by intraperitoneal injection of chloral hydrate (0.42
g/kg BW). The optic nerve (ON) was transected approxi-
mately 2 mm from the posterior eye pole without damaging
the retinal blood supply. In order to label RGCs, a small
piece of gel foam soaked in Fluorogold (FG, Fluorochrome,
Topical application by intravitreal injection is sufficient for G-CSF neuroprotection on retinal ganglion cellsFigure 4
Topical application by intravitreal injection is sufficient for G-CSF neuroprotection on retinal ganglion cells. G-
CSF was given either systemically by daily subcutaneous injection (20 or 40 μg/kg bodyweight per injection), or by direct appli-
cation to RGCs via intravitreal injection (500 ng in 2 μl per injection on day 0, 4, 7 and 10 after axotomy; first injection 2 h after 
axotomy). Leukocyte counts were determined one day before drug administration and after 14 days of treatment (n = 8 per 
group). Subcutaneous application resulted in the expected leukocytosis, while we could confirm that the intraocular G-CSF 
injection did not influence leukocyte counts (A). RGC survival was then determined accordingly after subcutaneous or intraoc-
ular G-CSF application (B). Both protocols lead to a comparable protective effect on axotomized RGCs in vivo. * p < 0.05 when 
compared to respective vehicle control; n.s. = not significant; i.o.: intraocular (intravitreal) injection.Page 7 of 10
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ON. Alternatively, specific Fluorogold staining was achieved
by injection of the tracer into the superior colliculus. On day
14, animals were sacrificed by injecting an overdose of chlo-
ral hydrate. The eyes were removed and dissected, removing
cornea, lens, and vitreous body. The eye bulb was then fixed
for 20 minutes in 4% PFA, followed by separation of the ret-
ina from the eye bulb. This was followed by flat-mounting
the retina on gelatine-coated glass slides incising the tissue to
four retinal quadrants. RGCs were examined under a fluores-
cence microscope (Axiovert 35; Carl Zeiss Meditec) using a
UV filter (365/420 nm) to detect Fluorogold fluorescence.
The number of FG – positive RGCs was determined by
counting them in 12 distinct areas of 62,500 μm2 each (three
areas per retinal quadrant at three different eccentricities of
one sixth, one half, five sixths of the retinal radius). Cell
counts were performed by two different blinded observers
and the average of their cell counts was calculated. Overesti-
mation of RGC density by retinal shrinkage due to i.o. injec-
tion was excluded before [33]. Animal experiments were
approved by appropriate German authorities (Bezirksre-
gierung Braunschweig).
Drug administration
For intravitreal drug administration, animals were anes-
thetized with diethyl ether. Via a glass microelectrode
with a tip diameter of 30 μm, G-CSF (Neupogen®,
AMGEN, Thousand Oaks, USA) or respective vehicle (250
mM sorbitol, 0.004% Tween-80 and 10 mM sodium ace-
tate buffer (pH 4,0))was injected into the vitreous space
(500 ng in 2 μl injection volume), puncturing the eye
behind the cornea-sclera junction and carefully avoiding
the lens as described [32]. Injections were performed on
days 0, 4, 7, and 10 after axotomy. Alternatively, G-CSF
was given subcutaneously once daily at a dose of 20 or 40
μg/kg bodyweight, or the respective vehicle was injected.
Immunohistochemistry
For immunohistochemical experiments, animals were
killed 3 days after surgery with an overdose of chloral
hydrate. The eyes were dissected and eye cups immedi-
ately fixed without cornea and lens for 1 hour in 4% PFA
in PBS at 4°C. Eye cups were immersed in 30% sucrose in
PBS overnight at 4°C and frozen in cutting compound
(Tissue-tek; Sakura Finetek, Torrance, CA) with liquid
nitrogen. Cryostat-cut sections (16 μm) were collected on
slides (Superfrost; Fisher Scientific, Pittsburgh, PA), dried
at 37°C, and stored at -20°C. Slides were then dried for 1
hour at 37°C, cryosections were incubated in 10% normal
goat serum (NGS, PAA) in PBS containing 0,3% Triton X-
100 (Roth, Karlsruhe, Germany), to block non-specific
binding. Sections were then washed three times in PBS
and incubated with primary antibody at 4°C overnight.
Immunoreactivity was visualized by incubating the sec-
tions with a secondary fluorescent antibody or with a
biotinylated secondary antibody after washing three times
with PBS followed by applying avidin-biotin-complex
(ABC-Elite; Vector Laboratories, CA, USA). Finally, sec-
tions were cover slipped (Fluka, Sigma-Aldrich, Buchs,
Switzerland). Primary antibody was directed against G-
CSFR (1:100, Santa Cruz Biotechnology, Santa Cruz, CA).
Goat anti-rabbit Cy3-conjugated IgG served as secondary
antibody (Dianova, Hamburg, Germany). Immunofluo-
rescence and DAB staining was imaged with an Axioplan
microscope (Carl Zeiss, Meditec).
Immunopanning and immunocytochemistry of RGCs
In vitro experiments using immunopurified retinal ganglion
cell culture were prepared as described previously [42].
Briefly, for immunopurified rat RGC culture, rat pups were
killed on postnatal day 8. Serum-free culture medium was
used (Neurobasal; Invitrogen-Gibco, Eggenstein, Germany)
supplemented with glutamine, cysteine, pyruvate, triio-
dothyronine, B-27 supplement and Sato (BSA, transferrine,
progesterone, putrescine, sodium selenite). During the first
24 hours, RGCs were additionally incubated with saturated
concentrations of forskolin, human BDNF, ciliary neuro-
trophic factor (CNTF), and insulin. The culture was with-
drawn from neurotrophins by change of medium on culture
day 1 and incubated with vehicle or the indicated concentra-
tion of G-CSF. G-CSF was diluted in cell culture medium
without neurotrophins to the respective final concentration
in the cell culture well.
The RGC survival rate was determined by a 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell
survival assay. MTT (5 mg/ml) was added to culture wells
(1:10) at culture day 3 and incubated at 37°C for 1 hour. Via-
bility of RGCs was assessed by counting six fields within a
culture well using a 20× objective by a blinded observer.
RGCs showing dense blue staining of cell bodies were con-
sidered to be MTT-positive. Survival of RGCs in the different
culture conditions was calculated as the mean number of
MTT-positive RGCs/mm2 in three wells per experiment and
per experimental condition on day 3. Results are expressed as
the percentage of additional survival compared to neuro-
trophin-deprived control RGCs on day 3.
For immunocytochemistry primary RGCs were seeded on
24 well plates (5000/well) and fixed with PFA 4% after 3
days. Blocking was performed with 10% NGS for 30 min.
Primary antibody (rabbit polyclonal antibody, SantaCruz,
sc-694) was diluted in 2% NGS 1:50 and incubated over-
night at 4°C. As secondary antibody, a goat-anti-rabbit
Cy3 (Dianova, diluted 1:250) that was incubated for 1 h
at room temperature was used. Coverslips were mounted
on object slides with moviol.
Reverse transcription and G-CSF receptor PCR from 
primary RGCs
RNA was prepared from primary RGCs by Qiagen RNA-
Easy columns. Reverse transcription was performed usingPage 8 of 10
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(Roche). For detection of the G-CSF receptor [GenBank:
NM_001106685] the following primers were used: rat-
GCSFR-frag32s (CCATTGTCCATCTTGGGGATC) and rat-
GCSFR-frag265as (CCTGGAAGCTGTTGTTCCATG) with
an expected product length of 233 bp. Cycling conditions
were as follows: 5 minutes at 94°C (only first cycle); 30
seconds at 94°C, 1 min at 66°C, 40 seconds at 72°C for
50 cycles; final elongation for 5 min at 72°.
Statistics
Data were expressed as the mean ± SEM. Statistical signif-
icance was assessed applying one-way ANOVA followed
by the Bonferroni's post hoc test (comparing RGC sur-
vival).
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